open access

Vol 2, No 5 (2013)
Review
Published online: 2013-10-25
Get Citation

Sodium-glucose co-transporter-2 (SGLT2) inhibitors: novel oral antidiabetic drugs

Błażej Przybysławski, Piotr Karbowiak, Jacek Rzeszotarski, Lech Walasek
Diabetologia Kliniczna 2013;2(5):191-197.

open access

Vol 2, No 5 (2013)
Review
Published online: 2013-10-25

Abstract

Introduction. Due to rising diabetes mellitus morbidity and inadequate glycemic control new therapeutic agents, targeting on different metabolic pathways, need to be developed.

Materials and methods. Gained renal glucose reuptake in patients with diabetes mellitus is one of the target.

Results. Sodium-glucose co-transporter-2 (SGLT2) inhibitors are able to affect this mechanism. SGLT2 localized in proximal renal tube are responsible for reuptake of 90% of glucose from the urine.

Conclusions. Inhibition of this transporting system induces glucosuria and decreases blood glucose level. Additionally SGLT2 inhibitors lead to body mass reduction and lower blood pressure. Most frequent adverse effects are genitourinary infections, particularly fungal. Long-term follow-up of patients with familial renal glucosuria (FRG), caused by genetic defect of SGLT2, has not revealed major abnormalities due to prolonged glucosuria.

Abstract

Introduction. Due to rising diabetes mellitus morbidity and inadequate glycemic control new therapeutic agents, targeting on different metabolic pathways, need to be developed.

Materials and methods. Gained renal glucose reuptake in patients with diabetes mellitus is one of the target.

Results. Sodium-glucose co-transporter-2 (SGLT2) inhibitors are able to affect this mechanism. SGLT2 localized in proximal renal tube are responsible for reuptake of 90% of glucose from the urine.

Conclusions. Inhibition of this transporting system induces glucosuria and decreases blood glucose level. Additionally SGLT2 inhibitors lead to body mass reduction and lower blood pressure. Most frequent adverse effects are genitourinary infections, particularly fungal. Long-term follow-up of patients with familial renal glucosuria (FRG), caused by genetic defect of SGLT2, has not revealed major abnormalities due to prolonged glucosuria.

Get Citation

Keywords

sodium-glucose transporter 2, glycosuria, glycosuria renal, diabetes mellitus, type 2, hypoglycemic agents

About this article
Title

Sodium-glucose co-transporter-2 (SGLT2) inhibitors: novel oral antidiabetic drugs

Journal

Clinical Diabetology

Issue

Vol 2, No 5 (2013)

Pages

191-197

Published online

2013-10-25

Bibliographic record

Diabetologia Kliniczna 2013;2(5):191-197.

Keywords

sodium-glucose transporter 2
glycosuria
glycosuria renal
diabetes mellitus
type 2
hypoglycemic agents

Authors

Błażej Przybysławski
Piotr Karbowiak
Jacek Rzeszotarski
Lech Walasek

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl